Stepping out of stealth mode, Treeline Biosciences, a Massachusetts-based oncology biotech, announced a $200 million Series A extension, bringing total funding to $1.1 billion. The company disclosed three early clinical-stage cancer drug candidates targeting lymphoma and solid tumors, including protein degraders and broad-spectrum KRAS inhibitors. Treeline’s ample financing and multipronged portfolio strategy position it to challenge traditional milestone-driven development models and seek sustained innovation across multiple therapeutic programs.